The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1466590
Case report: Identification of a novel TOR1AIP2::ETV6 transcript with FLT3-ITD mutation in acute myeloid leukemia progressed from myelodysplastic symdrome
Provisionally accepted- 1 Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of China, 214131, Wuxi, China
- 2 Changshu Hospital Affiliated to Soochow University, Changshu NO.1 People’s Hospital, Changshu, 215500, Jiangsu Province, China, Changshu, China
- 3 Department of Hematology, Affiliated Jianhu Hospital of Nantong University Xinglin College, Yancheng, 224700, China, Yancheng, China
- 4 Suzhou Jsuniwell Medical Laboratory, Suzhou, P.R. China, Suzhou, Liaoning Province, China
- 5 Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Suzhou, China
Acute myeloid leukemia (AML), mostly occurred in adults, is a challenging hematological malignancy. The occurrence and progression of AML are often accompanied with various gene fusions and/or mutations. Herein, we report the first case of TOR1AIP2::ETV6 fusion transcript with a translocation of t(1;12)(q25;p13) in AML progressed from myelodysplastic symdrome (MDS) combined with FLT3-ITD (internal tandem duplication) mutation. Further studies should put eyes on the biological functions of these novel chimeric products in disease onset and progression, as well as the potential as a monitoring marker in disease regression.
Keywords: Acute Myeloid Leukemia, Gene fusions, TOR1AIP2::ETV6, FLT3-ITD, Mutation
Received: 18 Jul 2024; Accepted: 06 Nov 2024.
Copyright: © 2024 Xia, Yang, Yu, Zhang, Wang, Sun, Chen, Wang, Chen, Gu and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jun Xia, Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of China, 214131, Wuxi, China
Guanqun Yang, Changshu Hospital Affiliated to Soochow University, Changshu NO.1 People’s Hospital, Changshu, 215500, Jiangsu Province, China, Changshu, China
Qingling Yu, Department of Hematology, Affiliated Jianhu Hospital of Nantong University Xinglin College, Yancheng, 224700, China, Yancheng, China
Hongli Sun, Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of China, 214131, Wuxi, China
Heng Chen, Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of China, 214131, Wuxi, China
Lingling Wang, Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of China, 214131, Wuxi, China
Ping Chen, Suzhou Jsuniwell Medical Laboratory, Suzhou, P.R. China, Suzhou, Liaoning Province, China
Kai-Li Gu, Suzhou Jsuniwell Medical Laboratory, Suzhou, P.R. China, Suzhou, Liaoning Province, China
Chao Sun, Department of Hematology, Affiliated Wuxi People’s Hospital, Nanjing Medical University, Wuxi, People’s Republic of China, 214131, Wuxi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.